Baxter Receives Marketing Authorisation
Selected Abstract
Baxter Receives Marketing Authorisation From the European Commission for ADVATE to Treat Haemophilia A; -- First Factor VIII Therapy Available in Europe with Innovative Processing to Help Address Safety Concerns --.
ZURICH, Switzerland, March 3 /PRNewswire/ -- Baxter Healthcare S.A. announced today that the European Commission has issued a Marketing Authorisation for ADVATE (Octocog Alfa Recombinant Coagulation Factor VIII). ADVATE is indicated for the prevention and control of bleeding episodes in people with ... March 3, 2004; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Baxter Receives Marketing Authorisation from SWISSMEDIC for ADVATE to Treat Haemophilia A.
2.
Baxter Receives Marketing Authorisation From the European Commission for ADVATE to Treat Haemophilia A; -- First Factor VIII Therapy Available in Europe with Innovative Processing to Help Address Safety Concerns --.
3.
Baxter Receives Marketing Authorisation from the European Commission for ADVATE to Treat Haemophilia A.
|
